Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
KRAS
Biotech
High dose of Cardiff's KRAS drug shows 64% ORR, sending stock up
Cardiff reported deeper tumor responses among the patients receiving the 30-mg dose of the biotech's drug compared to those receiving 20 mg.
Gabrielle Masson
Dec 10, 2024 4:05pm
Roche culls cough candidate, pivots KRAS program in Q3 update
Oct 23, 2024 6:35am
Allist pays Jacobio $21M, landing role in Chinese KRAS race
Aug 30, 2024 9:12am
Genentech sinks SHP2 pact, leaving Relay to race thinning field
Jul 17, 2024 8:01am
Erasca lays off 18%, swaps out KRAS program for fresh options
May 17, 2024 5:30am
BridgeBio taps VCs for $200M to fund cancer-focused spinout
May 2, 2024 7:00am
